Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more
Innoviva Inc (INVA) - Net Assets
Latest net assets as of December 2025: $1.17 Billion USD
Based on the latest financial reports, Innoviva Inc (INVA) has net assets worth $1.17 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.64 Billion) and total liabilities ($462.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.17 Billion |
| % of Total Assets | 71.73% |
| Annual Growth Rate | 6.84% |
| 5-Year Change | 123.0% |
| 10-Year Change | N/A |
| Growth Volatility | 106.04 |
Innoviva Inc - Net Assets Trend (2000–2025)
This chart illustrates how Innoviva Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innoviva Inc (2000–2025)
The table below shows the annual net assets of Innoviva Inc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.17 Billion | +69.69% |
| 2024-12-31 | $691.16 Million | +2.40% |
| 2023-12-31 | $674.96 Million | +19.29% |
| 2022-12-31 | $565.79 Million | +7.58% |
| 2021-12-31 | $525.93 Million | -13.47% |
| 2020-12-31 | $607.84 Million | +77.67% |
| 2019-12-31 | $342.12 Million | +115.10% |
| 2018-12-31 | $159.05 Million | +165.53% |
| 2017-12-31 | $-242.71 Million | +31.24% |
| 2016-12-31 | $-352.99 Million | -3.02% |
| 2015-12-31 | $-342.64 Million | -53.41% |
| 2014-12-31 | $-223.35 Million | -174.67% |
| 2013-12-31 | $299.12 Million | +92.95% |
| 2012-12-31 | $155.03 Million | +278.09% |
| 2011-12-31 | $-87.05 Million | -288.28% |
| 2010-12-31 | $-22.42 Million | +88.14% |
| 2009-12-31 | $-188.99 Million | -40.05% |
| 2008-12-31 | $-134.95 Million | -103.65% |
| 2007-12-31 | $-66.26 Million | -204.67% |
| 2006-12-31 | $63.31 Million | +6.25% |
| 2005-12-31 | $59.58 Million | -68.70% |
| 2004-12-31 | $190.37 Million | +163.55% |
| 2003-12-31 | $-299.57 Million | -29.16% |
| 2002-12-31 | $-231.93 Million | -203.45% |
| 2000-12-31 | $224.19 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innoviva Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 42066300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $269.37 Million | 22.97% |
| Common Stock | $747.00K | 0.06% |
| Other Components | $902.73 Million | 76.97% |
| Total Equity | $1.17 Billion | 100.00% |
Innoviva Inc Competitors by Market Cap
The table below lists competitors of Innoviva Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanbo Hospital Management Group Ltd. A
SHE:301293
|
$1.52 Billion |
|
NRW Holdings Limited
F:3NR
|
$1.52 Billion |
|
Hangjin Technology Co Ltd
SHE:000818
|
$1.52 Billion |
|
Stellar Bancorp, Inc.
NYSE:STEL
|
$1.52 Billion |
|
Heilongjiang Agriculture Co Ltd
SHG:600598
|
$1.52 Billion |
|
Shift4 Payments Inc
NYSE:FOUR
|
$1.52 Billion |
|
Inner Mongolia Furui Med Sci
SHE:300049
|
$1.52 Billion |
|
Terravest Capital Inc
TO:TVK
|
$1.52 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innoviva Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 691,159,000 to 1,172,841,000, a change of 481,682,000 (69.7%).
- Net income of 271,165,000 contributed positively to equity growth.
- Share repurchases of 4,675,000 reduced equity.
- New share issuances of 2,553,000 increased equity.
- Other factors increased equity by 212,639,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $271.17 Million | +23.12% |
| Share Repurchases | $4.67 Million | -0.4% |
| Share Issuances | $2.55 Million | +0.22% |
| Other Changes | $212.64 Million | +18.13% |
| Total Change | $- | 69.69% |
Book Value vs Market Value Analysis
This analysis compares Innoviva Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.58x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.37x to 1.58x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $58.90 | $21.89 | x |
| 2002-12-31 | $-36.61 | $21.89 | x |
| 2003-12-31 | $-44.00 | $21.89 | x |
| 2004-12-31 | $5.72 | $21.89 | x |
| 2005-12-31 | $1.12 | $21.89 | x |
| 2006-12-31 | $1.07 | $21.89 | x |
| 2007-12-31 | $-1.10 | $21.89 | x |
| 2008-12-31 | $-2.20 | $21.89 | x |
| 2009-12-31 | $-3.00 | $21.89 | x |
| 2010-12-31 | $-0.31 | $21.89 | x |
| 2011-12-31 | $-1.06 | $21.89 | x |
| 2012-12-31 | $1.71 | $21.89 | x |
| 2013-12-31 | $2.92 | $21.89 | x |
| 2014-12-31 | $-1.99 | $21.89 | x |
| 2015-12-31 | $-2.97 | $21.89 | x |
| 2016-12-31 | $-2.86 | $21.89 | x |
| 2017-12-31 | $-2.03 | $21.89 | x |
| 2018-12-31 | $1.35 | $21.89 | x |
| 2019-12-31 | $2.76 | $21.89 | x |
| 2020-12-31 | $4.75 | $21.89 | x |
| 2021-12-31 | $4.40 | $21.89 | x |
| 2022-12-31 | $5.94 | $21.89 | x |
| 2023-12-31 | $7.77 | $21.89 | x |
| 2024-12-31 | $9.32 | $21.89 | x |
| 2025-12-31 | $13.84 | $21.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innoviva Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 63.78%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.39x
- Recent ROE (23.12%) is above the historical average (-6.55%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -42.35% | 0.00% | 0.00x | 1.10x | $-117.35 Million |
| 2002 | 0.00% | -50786.54% | 0.00x | 0.00x | $-56.03 Million |
| 2003 | 0.00% | -1957.92% | 0.03x | 0.00x | $-40.63 Million |
| 2004 | -53.92% | -1148.26% | 0.03x | 1.50x | $-121.69 Million |
| 2005 | -240.27% | -1187.69% | 0.05x | 3.77x | $-149.12 Million |
| 2006 | -262.27% | -847.73% | 0.07x | 4.15x | $-172.38 Million |
| 2007 | 0.00% | -727.19% | 0.14x | 0.00x | $-153.37 Million |
| 2008 | 0.00% | -405.45% | 0.10x | 0.00x | $-80.15 Million |
| 2009 | 0.00% | -349.97% | 0.13x | 0.00x | $-66.40 Million |
| 2010 | 0.00% | -346.21% | 0.07x | 0.00x | $-81.62 Million |
| 2011 | 0.00% | -470.56% | 0.09x | 0.00x | $-106.64 Million |
| 2012 | -11.96% | -13.66% | 0.37x | 2.38x | $-34.04 Million |
| 2013 | -57.07% | -3587.66% | 0.01x | 2.28x | $-200.61 Million |
| 2014 | 0.00% | -1997.68% | 0.02x | 0.00x | $-146.13 Million |
| 2015 | 0.00% | -34.77% | 0.13x | 0.00x | $15.50 Million |
| 2016 | 0.00% | 44.57% | 0.35x | 0.00x | $94.84 Million |
| 2017 | 0.00% | 61.76% | 0.59x | 0.00x | $158.43 Million |
| 2018 | 257.23% | 151.36% | 0.48x | 3.57x | $379.70 Million |
| 2019 | 50.17% | 60.26% | 0.36x | 2.31x | $125.94 Million |
| 2020 | 41.56% | 66.63% | 0.34x | 1.85x | $170.41 Million |
| 2021 | 64.10% | 67.84% | 0.42x | 2.23x | $224.38 Million |
| 2022 | 37.81% | 64.56% | 0.27x | 2.18x | $157.34 Million |
| 2023 | 26.63% | 57.89% | 0.25x | 1.84x | $112.23 Million |
| 2024 | 3.38% | 6.52% | 0.28x | 1.88x | $-45.72 Million |
| 2025 | 23.12% | 63.78% | 0.26x | 1.39x | $153.88 Million |
Industry Comparison
This section compares Innoviva Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innoviva Inc (INVA) | $1.17 Billion | -42.35% | 0.39x | $1.52 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |